Baird analyst Joel Beatty raised the firm’s price target on Sage Therapeutics (SAGE) to $9 from $7 and keeps a Neutral rating on the shares. The firm updated its target to reflect its proposed acquisition price.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SAGE:
- H.C. Wainwright sees potential competition for Sage from Biogen
- Sage Therapeutics price target raised to $9 from $8 at Truist
- Hold Rating on SAGE Therapeutics Amid Uncertainty and Acquisition Developments
- Sage Therapeutics price target raised to $8.50 from $8 at Canaccord
- Hold Rating on SAGE Therapeutics Amid Acquisition Offer and CVR Uncertainties